Rapamycin Plus Bevacizumab in Advanced Cancers

Inclusion Criteria: * Metastatic or unresectable solid tumor for which standard treatments do not exist or are no longer effective * Performance status of 0-1 * Measurable or non-measurable disease * Life expectancy of at least 12 weeks * No anticipated need of other cancer treatments within the next 4 weeks * 18 years or older * Negative pregnancy test for women able to have children, agreement to use a medically accepted birth control method while receiving the study drugs and for at least 2 weeks after stopping, not breast feeding * Ability to understand and willingness to sign a written informed consent document * No evidence of bleeding diathesis * Patients without lung cancer receiving anti-coagulation treatment can participate * Adequate organ and marrow function: * ALT and AST less than or equal to 2.5 times the institutional ULN (less than 5 times for patients with liver involvement) * hemoglobin at least 9g/dL * absolute neutrophil count at least 1,500/µL * platelets at least 100,000/µL * total bilirubin less than or equal to 1.5 times the institutional ULN * creatinine less than or equal to 1.5 times the institutional ULN Exclusion Criteria: * Prior treatment with both bevacizumab and an mTOR inhibitor is not allowed. Prior treatment with both bevacizumab OR mTOR inhibitor (including rapamycin) is allowed. Patients who had a grade 3 or greater side effect with either bevacizumab or an mTOR inhibitor cannot take part in this study. * Chemotherapy or Immunotherapy within the 4 weeks of study start * Radiotherapy within 14 days of study start * Cannot be receiving any other investigational drugs or any other cancer treatments while on study (with the exception of androgen ablating agents for patients with prostate cancer). * Patients with squamous non-small cell lung cancer (NSCLC) * Patients with lung cancer or lung metastases: * on full dose anticoagulation * taking 325mg aspirin per day * on non-steroidal anti-inflammatory agents * HIV positive patients receiving combination anti-retroviral therapy are excluded due to potential for serious infections while taking marrow suppressing agents * Ongoing illness or medical exclusions, including but not limited to: * active or ongoing infection * symptomatic congestive heart failure * uncontrolled hypertension despite optimal medical management * cardiac arrhythmia except paroxysmal atrial fibrillation * psychiatric illness/social situations that would limit compliance with study requirements * history of organ allograft, bone marrow or peripheral blood stem cell transplant * known or suspect allergy to bevacizumab or rapamycin * seizure disorder treated with steroid or anticonvulsant therapy * thrombotic or embolic events within 6 months of starting study * pulmonary hemorrhage/bleeding within 12 weeks of starting study (grade 3 event within 4 weeks of first dose of drug). Patients with a history of pulmonary hemorrhage/bleeding cannot be on full dose anticoagulation. * pulmonary fibrosis or interstitial lung disease * serious non-healing wound, ulcer or bone fracture * Major surgery, open biopsy or a traumatic injury within 4 weeks of starting study drug * anticipated need for major surgery while on-study * current use of any herbal supplements or rifampin (rifampicin) * prior history of hypertensive crisis or hypertensive encephalopathy * history of myocardial infarction or unstable angina within 6 months of starting study * known CNS disease * significant vascular disease * symptomatic peripheral vascular disease * evidence of bleeding diathesis or coagulopathy * core biopsy or other minor surgical procedure (except placement of vascular access device) within 7 days of starting study * history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of study start * proteinuria at screening